<DOC>
	<DOCNO>NCT00110266</DOCNO>
	<brief_summary>The purpose trial examine safety efficacy deferasirox patient Myelodysplastic Syndrome ( MDS ) chronic iron overload blood transfusion .</brief_summary>
	<brief_title>Study Deferasirox Treatment Transfusional Iron Overload Myelodysplastic Patients</brief_title>
	<detailed_description>Study entry require diagnosis low intermediate ( INT-1 ) risk MDS per International Prognostic Scoring System ( IPSS ) criteria serum ferritin ≥ 1000 ng/mL . Patients must least 30 prior red blood cell transfusion . Deferasirox administer initial dose 20 mg/kg orally per day . Patient transfusion history least three complete blood count ( CBC ) value must available 12 week prior study registration patient MDS chronic iron overload blood transfusion .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<mesh_term>Chelating Agents</mesh_term>
	<criteria>Male female patient low intermediate ( INT1 ) risk MDS Patients EITHER naïve iron chelation OR prior treatment deferoxamine ( DFO ) . Age great equal 18 year Availability transfusion record 12 week prior registration A lifetime minimum 30 previous pack red blood cell transfusion Availability least three CBC value ( pretransfusion ) 12 week prior registration Serum Ferritin : For entry screening period , serum ferritin ≥ 1000 ng/mL least two occasion , least two week apart , prior year . Serum ferritin ≥ 1000 ng/mL screen via central lab . Life expectancy ≥ 6 month Sexually active woman must use effective method contraception , must undergo clinically document total hysterectomy and/or oophorectomy , tubal ligation postmenopausal ( define amenorrhea least 12 month ) Able provide write informed consent Serum creatinine upper limit normal ALT &gt; 500 U/L screen Clinical laboratory evidence active Hepatitis B C Urinary protein/creatinine ratio &gt; 0.5 mg/mg History HIV positive test result ( ELISA Western blot ) ECOG Performance Status &gt; 2 Patients uncontrolled systemic hypertension Unstable cardiac disease control standard medical therapy Patients diagnosis history clinically relevant ocular toxicity relate iron chelation Systemic disease ( cardiovascular , renal , hepatic , etc . ) would prevent study treatment Pregnancy breast feeding Treatment systemic investigational drug within past 4 week topical investigational drug within past 7 day Other surgical medical condition might significantly alter absorption , distribution , metabolism excretion study drug History noncompliance medical regimens patient consider potentially unreliable and/or cooperative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ICL670</keyword>
	<keyword>Deferasirox</keyword>
	<keyword>Iron chelation</keyword>
	<keyword>Chelator</keyword>
	<keyword>Desferal</keyword>
</DOC>